Categories Earnings

Xerox CEO faces suit after pushing Fujifilm deal

Xerox (XRX) chief Jeff Jacobson faces a fresh lawsuit from a major shareholder of the company for pursuing a deal with Japan’s Fujifilm even after the board advised him to drop negotiations.

The CEO was often blamed for his alleged underperformance during his tenure, with the company even considering firing him. It was then that the company struck a deal with Fujifilm. This deal grabbed the spotlight and was seen as one of those transactions that could help Jacobson keep his job. However, he was suggested to stop all dealings with the Japanese firm.

The new lawsuit filed by a major shareholder, Darwin Deason, suggests that Jacobson went ahead and chased the deal, thereby going against the board, a report by the Wall Street Journal alleged. The company, however, flatly denied these allegations.

According to the lawsuit, Jacobson — who replaced Ursula Burns — rushed with the deal as he would gain a major control as a CEO once the merger took place. This was highly criticized by Deason as well as Carl Icahn — who are aggressively working towards introducing major changes at the company.

In January this year, Deason opposed the $6.1-billion deal between Fujifilm and Xerox stating the agreement undervalued Xerox. Yet, The US company went ahead signing the deal with its old joint-venture partner Fuji Xerox, with an aim to optimize expenses in a declining office printing equipment market.

Despite all these claims and allegations, Jacobson continues to be the CEO of the company, thanks to the deal. But it has clearly created a rift between the management and the board, which is expected to have grave repercussions in the coming days.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top